Physician profile
Stella Lai
NPI 1588906663
$7,225.82
in general payments reported to CMS, 2019-2025
21 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $376 · 2021: $545 · 2022: $1,402 · 2023: $1,527 · 2024: $705 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,375.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,695.01 | 2021-2025 | |
| Neurelis, INC. | $687.73 | 2022-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $631.77 | 2021-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $468.26 | 2019-2021 | |
| Pfizer INC. | $443.00 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $403.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $349.84 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Biogen, INC. | $263.64 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Biohaven Pharmaceuticals, INC. | $187.68 | 2021 | |
| Livanova USA, INC. | $185.18 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $155.13 | 2021-2025 | Crexont, Rytary |
| Sunovion Pharmaceuticals INC. | $155.02 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $120.74 | 2023-2024 | Aptiom |
| Ucb, INC. | $119.08 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Lilly USA, LLC | $93.64 | 2022-2023 | Amyvid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $85.28 | 2019-2022 | |
| Sk Life Science, INC. | $83.81 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $31.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.52 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $23.28 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.03 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.